These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35131437)

  • 21. Development of an Alcohol Dilution-Lyophilization Method for the Preparation of mRNA-LNPs with Improved Storage Stability.
    Shirane D; Tanaka H; Sakurai Y; Taneichi S; Nakai Y; Tange K; Ishii I; Akita H
    Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles.
    Wang J; Zhang Y; Dong S; Zha W; Liu C; Wang Y; Jiang Y; Xing H; Li X
    Int J Pharm; 2023 Jul; 642():123155. PubMed ID: 37402442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization.
    Ball RL; Bajaj P; Whitehead KA
    Int J Nanomedicine; 2017; 12():305-315. PubMed ID: 28115848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.
    Zamani P; Mashreghi M; Rezazade Bazaz M; Zargari S; Alizadeh F; Dorrigiv M; Abdoli A; Aminianfar H; Hatamipour M; Zarqi J; Behboodifar S; Samsami Y; Khorshid Sokhangouy S; Sefidbakht Y; Uskoković V; Rezayat SM; Jaafari MR; Mozaffari-Jovin S
    J Control Release; 2023 Aug; 360():316-334. PubMed ID: 37355212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
    Takanashi A; Pouton CW; Al-Wassiti H
    Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elucidation of lipid nanoparticle surface structure in mRNA vaccines.
    Wang MM; Wappelhorst CN; Jensen EL; Chi YT; Rouse JC; Zou Q
    Sci Rep; 2023 Oct; 13(1):16744. PubMed ID: 37798336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of lipid composition on RNA-Lipid nanoparticle properties and their sensitivity to thin-film freezing and drying.
    AboulFotouh K; Southard B; Dao HM; Xu H; Moon C; Williams Iii RO; Cui Z
    Int J Pharm; 2024 Jan; 650():123688. PubMed ID: 38070660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery.
    Ngamcherdtrakul W; Sangvanich T; Reda M; Gu S; Bejan D; Yantasee W
    Int J Nanomedicine; 2018; 13():4015-4027. PubMed ID: 30022824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innate immune mechanisms of mRNA vaccines.
    Verbeke R; Hogan MJ; Loré K; Pardi N
    Immunity; 2022 Nov; 55(11):1993-2005. PubMed ID: 36351374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines.
    Li Z; Zhang XQ; Ho W; Li F; Gao M; Bai X; Xu X
    ACS Nano; 2022 Nov; 16(11):18936-18950. PubMed ID: 36269150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
    Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
    J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes.
    Arevalo CP; Bolton MJ; Le Sage V; Ye N; Furey C; Muramatsu H; Alameh MG; Pardi N; Drapeau EM; Parkhouse K; Garretson T; Morris JS; Moncla LH; Tam YK; Fan SHY; Lakdawala SS; Weissman D; Hensley SE
    Science; 2022 Nov; 378(6622):899-904. PubMed ID: 36423275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Principles for designing an optimal mRNA lipid nanoparticle vaccine.
    Kon E; Elia U; Peer D
    Curr Opin Biotechnol; 2022 Feb; 73():329-336. PubMed ID: 34715546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery Strategies for mRNA Vaccines.
    Ramachandran S; Satapathy SR; Dutta T
    Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses.
    Alameh MG; Tombácz I; Bettini E; Lederer K; Sittplangkoon C; Wilmore JR; Gaudette BT; Soliman OY; Pine M; Hicks P; Manzoni TB; Knox JJ; Johnson JL; Laczkó D; Muramatsu H; Davis B; Meng W; Rosenfeld AM; Strohmeier S; Lin PJC; Mui BL; Tam YK; Karikó K; Jacquet A; Krammer F; Bates P; Cancro MP; Weissman D; Luning Prak ET; Allman D; Locci M; Pardi N
    Immunity; 2021 Dec; 54(12):2877-2892.e7. PubMed ID: 34852217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications.
    Goldman RL; Vittala Murthy NT; Northen TP; Balakrishnan A; Chivukula S; Danz H; Tibbitts T; Dias A; Vargas J; Cooper D; Gopani H; Beaulieu A; Kalnin KV; Plitnik T; Karmakar S; Dasari R; Landis R; Karve S; DeRosa F
    Biomaterials; 2023 Oct; 301():122243. PubMed ID: 37480759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing mRNA for Therapy.
    Karikó K
    Keio J Med; 2022; 71(1):31. PubMed ID: 35342149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery.
    Cui L; Pereira S; Sonzini S; van Pelt S; Romanelli SM; Liang L; Ulkoski D; Krishnamurthy VR; Brannigan E; Brankin C; Desai AS
    Nanoscale; 2022 Jan; 14(4):1480-1491. PubMed ID: 35024714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs.
    Suzuki Y; Ishihara H
    Drug Metab Pharmacokinet; 2021 Dec; 41():100424. PubMed ID: 34757287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.